General product questions - Henkel Adhesives
An IDH number (International Data Harmonization) is the corresponding new Henkel part number associated with the LOCTITE ® item numbers. It is a global numbering system, generally composed of 6-digits with some exceptions.
Reference ID: 4847005 - Food and Drug Administration
Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal if not treated. If differentiation syndrome is suspected, initiate corticosteroid...
IDHIFA®: For Relapsed / Refractory Acute Myeloid Leukemia
IDHIFA ® is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment (s). It is not known if IDHIFA is safe and effective in children.
Finding product documents - Henkel Adhesives
Here you can find help with where to find documentation & information such as TDS, SDS, certificates, & approvals for Henkel products on this site.
FDA approves new targeted treatment for relapsed or refractory …
The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic...
FDA approves olutasidenib for relapsed or refractory acute …
On December 1, 2022, the Food and Drug Administration (FDA) approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible...
SEAL ID Description FG IDH SAP PKG IDH Previous PKG IDH Date Die-Cut No. Barcode Packaging Type Print Technology white SBU ... H&S Improvment MOC Label Base Label 1953046 Printer Name 2974274 FT2034248A-4 base label Thermal Printing / black colour printing FT2974274A-1 PMS 428 PMS 485 Black XXXXX XXXXX XXXXX XXXXX XXXXX XXXXX 3rd …
FDA approves vorasidenib for Grade 2 astrocytoma or …
On August 6, 2024, the Food and Drug Administration approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2)...
Ivosidenib off-label use for IDH mutant gliomas: The MD …
Results: From August 2018 to December 2022, we identified 13 patients with IDH-mutant glioma prescribed ivosidenib 500mg daily off-label. Four patients did not receive treatment: two were too sick soon after ivosidenib prescribed, and two were not able to get financial coverage.
Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid …
Oct 5, 2019 · Ivosidenib is the first approved oral, targeted, small-molecule inhibitor of the isocitrate dehydrogenase 1 (IDH1) mutation seen in AML. IDH1 mutations have been associated with significantly worse outcomes in disease-free survival, relapse-free survival, and overall survival (NCCN, 2018).